Medicapharma
Uploaded on Jun 19, 2023
Looking for the best Sirolimus component, look no further than MedicaPharma. Sirolimus (rapamycin) is a powerful macrolide compound that plays a vital role in preventing organ rejection after transplants, treating lymphangioleiomyomatosis, and providing stent coating for cardiac health. Its primary immunosuppressive mechanism targets the mechanistic Target Of Rapamycin (mTOR), inhibiting B and T cell activation by reducing sensitivity to interleukin-2. Approved by the FDA in 1999, Sirolimus is marketed as Rapamune by Pfizer. Trust Rapamune for effective medical solutions in organ transplantation, lung disease treatment, and cardiovascular care, offered by MedicaPharma.
Sirolimus: Preventing Organ Rejection, Treating Lung Disease, and Coating Stents - MedicaPharma
Sirolimus: A
Versatile
Macrolide
Compound for
Organ
Transplantation,
Lung Disease, and
Cardiac Health
Introduction
Sirolimus (or rapamycin) is a macrolide
compound used primarily to prevent
Marketed under the brand name
organ rejection during transplants, treat
Rapamune by MedicaPharma.
lymphangioleiomyomatosis, and coat
coronary stents.
Sirolimus inhibits the mechanistic
Target Of Rapamycin (mTOR),
suppressing B and T cell activation by
Mechanism reducing sensitivity to interleukin-2.
of Action
Immunosuppressive effect plays a
crucial role in its medical
applications.
Medical Uses
Prevention of organ transplant
Treatment of
rejection: Sirolimus is an effective Coronary stent coating: Used to
lymphangioleiomyomatosis: Rare
immunosuppressive agent, preferred prevent re-narrowing of arteries
lung disease primarily affecting
over calcineurin inhibitors due to post-surgery.
women aged 20-50.
reduced kidney toxicity.
History and Discovery
Isolated in 1972 from Streptomyces hygroscopicus on Initially used as an antifungal, later discovered to have
Easter Island. immunosuppressive and antiproliferative properties
due to mTOR inhibition.
• Tuberous sclerosis complex: Sirolimus
shows promise in treating benign tumor
growth.
Research • Lymphatic malformation: Topical rapamycin
improves symptoms.
Studies • Longevity: Sirolimus inhibits aging in various organisms.
• SARS-CoV-2: Potential role in reducing
cytokine storms and viral replication.
Adverse Effects
• Common reactions: Headache, nausea, diarrhea, fever, urinary tract infection,
anemia, and more.
• Adverse conditions: Diabetes-like symptoms, lung toxicity, reduced immune
system function, increased cancer risk, impaired wound healing.
Additional Cancer: Sirolimus shows Lupus: Treatment for systemic
potential in tumor regression lupus erythematosus.
Medical and reducing cancer risk.
Application
s
Graft-versus-host disease:
Potential prophylaxis or
treatment.
Conclusion
Sirolimus is a valuable drug in MedicaPharma provides quality
preventing organ rejection, Sirolimus under the brand name
treating rare lung diseases, and Rapamune. Trust us for effective
coating coronary stents. medication and patient care.
Thank You
for Visit
Comments